文献速递银屑病与炎症性皮肤病

依奇珠单抗治疗银屑病5年长期疗效与安全性:UNCOVER-3随机对照试验分析

Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial.
PubMed 文献 · J Am Acad Dermatol · 2020-11-28

UNCOVER-3试验5年分析评估依奇珠单抗(IXE)批准剂量治疗中重度斑块状银屑病的长期疗效与安全性。第264周时,78.8%/67.1%/46.2%患者达到PASI 75/90/100应答,sPGA 0/1和0应答率分别为69.2%和45.3%,感染为最常见不良事件(72.7%)。结论认为IXE在264周内显示持续疗效和一致的安全性。

要点

  • IXE批准剂量治疗至264周仍维持高比例PASI应答。
  • 感染是最常见治疗中出现的不良事件,发生率为72.7%。
  • 第12周后缺乏对照治疗组,长期比较受限。

核心结论

  • 依奇珠单抗在批准剂量下治疗至264周显示持续疗效和一致的安全性。

研究设计与样本

  • UNCOVER-3(NCT01646177)随机对照试验的5年分析,共纳入1346例患者。
  • 患者按1:2:2:2随机接受安慰剂、依那西普50 mg每周两次、或IXE 80 mg每2周/每4周(初始160 mg)。
  • 第12周进入长期扩展期,IXE每4周给药,第60周后可升级为每2周。

主要发现

  • 第264周时,批准剂量IXE每2周/每4周组(n=385)达到PASI 75/90/100应答的比例分别为78.8%/67.1%/46.2%。
  • 第264周时,sPGA 0/1和0应答率分别为69.2%和45.3%。
  • 感染是最常见的治疗中出现的不良事件,发生于72.7%的患者。

关键数值与推荐

  • 疗效采用改良无应答者填补法分析意向治疗人群中IXE每2周/每4周组。
  • 安全性分析纳入至少接受1剂IXE每2周或每4周的患者。

临床怎么用

  • 支持IXE批准剂量用于银屑病长期治疗,疗效可维持至5年。
  • 长期用药需关注感染风险,但安全性特征与既往一致。

局限性

  • 第12周后缺乏对照治疗组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the efficacy and safety of the approved ixekizumab (IXE) dose over 5 years from UNCOVER-3 (NCT01646177). METHODS: Patients (N = 1346) were randomized 1:2:2:2 to receive subcutaneous injections of placebo, etanercept 50 mg twice weekly, or IXE 80 mg every 2 weeks or every 4 weeks after an initial dose of IXE 160 mg, respectively. At week 12, patients entered the long-term extension period with dosing of IXE every 4 weeks and could escalate to every 2 weeks after week 60. Efficacy was reported for the IXE every 2 weeks/every 4 weeks group of the intent-to-treat population. Safety was reported for patients who received at least 1 dose of IXE every 2 or every 4 weeks. RESULTS: Using modified nonresponder imputation, 78.8%/67.1%/46.2% of patients receiving the approved dose of IXE every 2 weeks/every 4 weeks (n = 385) achieved ≥75%, ≥90%, or 100% improvement from baseline in the Psoriasis Area and Severity Index, respectively, at week 264; static Physician's Global Assessment score of 0/1 and 0 responses were 69.2% and 45.3%, respectively. Infections were the most observed treatment-emergent adverse event (72.7% of patients). LIMITATIONS: Lack of comparison treatment group after week 12. CONCLUSION: IXE demonstrates sustained efficacy and consistent safety through 264 weeks in patients using the approved dose.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2020. PMID: 33253833. doi:10.1016/j.jaad.2020.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。